Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (137)	4/19/1999 12:29:00 PM
From: Jim Oravetz	Read Replies (2) of 370

Vion Announces Encore Access of Conference Call from 4/16-21. To listen to Encore, participants should call (800) 642-1687 or locally (706) 645-9291 and enter conference id #162550. Takes 25-30 min. or so. Some interesting info, 3-4 post CC questions asked. Company is still aggressively looking for an additional $12-15M to continue product development and trials. 15M shares out/ 26M fully diluted via options, warrants etc. Class A - 25% still outstanding(1.2M). Class B - only 60% retired. Both have redemption calls if price rises A: $7.xx B: $9.xx >30 days. Earlist TAPET NDA -- end of 2002 (if all testing goes as planned, of course). Trials may start this summer with tox. results mostly from skin and breast cancer patients, where access/visibility is easier. Plan on concentrating on product development rather than sales and marketing. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next